Sarah Lowther caught up with Cathal Friel to learn more about the company and Orphan drugs, during the interview Friel shared his ambition of becoming Europe’s leading rare disease and orphan drug focused pharma services company who’s management team has widespread, extensive industry and financial expertise.
We recently wrote about Open Orphan, you can read it here
The orphan drug sector is booming and is expected to grow 2x faster than the non-orphan prescription drug sector. Therefore, Open Orphan will capitalise upon this underlying growth as we rapidly build a full-service leading European rare/orphan focused pharma services company.
You can hear the latest podcast with the CEO of Open Orphan Cathal Friel here.
The author was remunerated but does not hold shares in the company